InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,344.39
(
0.00%
)
US TECH 100
18,066.40
(
0.28%
)
Dow Jones
39,357.01
(
-0.36%
)
Brent Oil
81.32
(
-0.36%
)
Bitcoin
59,053.34
(
-0.51%
)
Post# of 252864
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 835
Posts 120262
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jackrmormon post# 114640

Saturday, 02/12/2011 11:58:59 PM

Saturday, February 12, 2011 11:58:59 PM

Post# of 252864
Re: FoB opportunities for MNTA

Don't know the patent expiries but have to believe an RA FOB is inevitable. Then Rituxan?

The TNF-alpha class includes three biologics among the world’s seven biggest-selling drugs—Remicade (#3), Enbrel (#5), and Humira (#7)—so it’s reasonable to surmise that MNTA has its sights trained on this class. Enbrel is already off-patent in the US, and Remicade will be off-patent soon—long before anyone could bring an FoB to market. Humira goes off-patent in the US in 2016.

Rituxan strikes me as an unattractive FoB program for MNTA because there are already several announced biosimilars and biobetters. Regards, Dew

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up